Monovalent vaccine outperforms bivalent in fighting new Omicron variants

New U.S. study finds mRNA-1273.815, a monovalent vaccine targeting the Omicron XBB.1.5 variant, generates higher neutralizing antibody titers compared to its bivalent counterpart. The study supports updating to an XBB.1.5-based monovalent vaccine for the 2023-24 campaign to combat emerging variants.

J&J leads pharma companies in brand rankings, topping Roche, Bayer and Pfizer amid overall industry decline

Johnson & Johnson held on to the top spot on Brand Finance’s list of most valuable pharmaceutical brands again this year, and overtook Pfizer for

July 6, 2023

Invitae test for hereditary cancers gains FDA de novo nod

Dive Brief: Genetic testing company Invitae has received de novo authorization from the Food and Drug Administration for an in vitro diagnostic test that can

October 3, 2023

New method accelerates drug discovery from years to months

Researchers from the University of Cincinnati College of Medicine and Cincinnati Children’s Hospital have found a new method to increase both speed and success rates

August 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.